Literature DB >> 14734445

Reducing the immune response to immunotoxin.

Arthur E Frankel1.   

Abstract

Mesh:

Substances:

Year:  2004        PMID: 14734445     DOI: 10.1158/1078-0432.ccr-1216-3

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  5 in total

1.  Construction and characterization of novel, completely human serine protease therapeutics targeting Her2/neu.

Authors:  Yu Cao; Khalid A Mohamedali; John W Marks; Lawrence H Cheung; Walter N Hittelman; Michael G Rosenblum
Journal:  Mol Cancer Ther       Date:  2013-03-14       Impact factor: 6.261

2.  Initial characterization of an immunotoxin constructed from domains II and III of cholera exotoxin.

Authors:  Robert Sarnovsky; Tara Tendler; Matheusz Makowski; Maureen Kiley; Antonella Antignani; Roberta Traini; Jingli Zhang; Raffit Hassan; David J FitzGerald
Journal:  Cancer Immunol Immunother       Date:  2009-11-29       Impact factor: 6.968

3.  Enhanced cytotoxicity of an anti-transferrin receptor IgG3-avidin fusion protein in combination with gambogic acid against human malignant hematopoietic cells: functional relevance of iron, the receptor, and reactive oxygen species.

Authors:  E Ortiz-Sánchez; T R Daniels; G Helguera; O Martinez-Maza; B Bonavida; M L Penichet
Journal:  Leukemia       Date:  2008-10-23       Impact factor: 11.528

Review 4.  Targeting of Tumor Neovasculature with GrB/VEGF121, a Novel Cytotoxic Fusion Protein.

Authors:  Khalid A Mohamedali; Michael G Rosenblum
Journal:  Biomedicines       Date:  2017-07-17

5.  Sequential optimization of methotrexate encapsulation in micellar nano-networks of polyethyleneimine ionomer containing redox-sensitive cross-links.

Authors:  Samira Sadat Abolmaali; Ali Tamaddon; Gholamhossein Yousefi; Katayoun Javidnia; Rasoul Dinarvand
Journal:  Int J Nanomedicine       Date:  2014-06-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.